Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

AIMS To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example. METHODS Data from three studies including 115 human immunodeficiency virus-infected South African adults were used. Patients were on antiretroviral therapy regimens including 200 mg nevirapine twice daily and sampled at steady state. A development process was suggested, implemented in NONMEM7 and the final model evaluated with an external data set. RESULTS A stepwise approach proved efficient. Model development started with the intensively sampled data. Data were added sequentially, using visual predictive checks for inspecting their compatibility with the existing model. Covariate exploration was carried out, and auxiliary regression models were designed for imputation of missing covariates. Nevirapine pharmacokinetics was described by a one-compartment model with absorption through two transit compartments. Body size was accounted for using allometric scaling. The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter. Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h. Concomitant antitubercular treatment including rifampicin typically decreased bioavailability by 39%, with significant between-subject variability. Visual predictive checks of external validation data indicated good predictive performance. CONCLUSIONS The development strategy succeeded in integrating data from different sources to produce a model with robust parameter estimates. This work paves the way for the creation of a nevirapine mega-model, including additional data from numerous diverse sources.

[1]  Jing Yuan,et al.  Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine , 2011, Pharmacogenetics and genomics.

[2]  G. Maartens,et al.  Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients , 2011, Antimicrobial Agents and Chemotherapy.

[3]  M. Youle,et al.  Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals , 2011, The Journal of antimicrobial chemotherapy.

[4]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[5]  T. Snyman,et al.  Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients , 2010, AIDS research and therapy.

[6]  C. Verstuyft,et al.  Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients , 2010, Antimicrobial Agents and Chemotherapy.

[7]  G. Maartens,et al.  Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study , 2010, AIDS research and therapy.

[8]  A. Efron,et al.  Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy , 2010, AIDS.

[9]  N. Ford,et al.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa , 2010, AIDS.

[10]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[11]  S. Khoo,et al.  Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. , 2009, The Journal of antimicrobial chemotherapy.

[12]  P. Perre,et al.  Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV‐infected patients: a population approach , 2009, HIV medicine.

[13]  S. Richardson,et al.  Bayesian graphical models for regression on multiple data sets with different variables , 2008, Biostatistics.

[14]  B. Clotet,et al.  Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. , 2008, The Journal of antimicrobial chemotherapy.

[15]  G. Maartens,et al.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. , 2008, JAMA.

[16]  G. Maartens,et al.  Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa , 2008, Antiviral therapy.

[17]  T. Harrer,et al.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.

[18]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[19]  G. Maartens,et al.  Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. , 2007, The Journal of antimicrobial chemotherapy.

[20]  S. Spector,et al.  CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children , 2007, AIDS.

[21]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  R. Chaisson,et al.  Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B , 2007, AIDS.

[23]  Leon Aarons,et al.  Propagation of Population PK and PD Information Using a Bayesian Approach: Dealing with Non-Exchangeability , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  Leon Aarons,et al.  Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  S. Khoo,et al.  Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals , 2005, Clinical pharmacology and therapeutics.

[26]  F. van Leth,et al.  Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study , 2005, Antiviral therapy.

[27]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[28]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[29]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[30]  H. Coovadia,et al.  MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu‐Natal, South Africa , 2003, Clinical pharmacology and therapeutics.

[31]  F. Aweeka,et al.  An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. , 2003, Journal of pharmaceutical and biomedical analysis.

[32]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[33]  Mats O. Karlsson,et al.  Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[34]  J. Beijnen,et al.  Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. , 2002, British journal of clinical pharmacology.

[35]  Michael D. Johnson,et al.  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.

[36]  P. Reiss,et al.  The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals , 2000, AIDS.

[37]  T. Macgregor,et al.  Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection , 2000, AAPS PharmSci.

[38]  J Wakefield,et al.  The Combination of Population Pharmacokinetic Studies , 2000, Biometrics.

[39]  J. Boissel,et al.  Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? , 2000, Journal of pharmaceutical sciences.

[40]  R H Levy,et al.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[41]  T. Macgregor,et al.  Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers , 1999, Biopharmaceutics & drug disposition.

[42]  T. Macgregor,et al.  Disposition and biotransformation of the antiretroviral drug nevirapine in humans. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[43]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[44]  R. Murphy,et al.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. , 1999, The Journal of infectious diseases.

[45]  Lewis B. Sheiner,et al.  Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients , 1999, Antimicrobial Agents and Chemotherapy.

[46]  J. Beijnen,et al.  Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[47]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[48]  Jos H. Beijnen,et al.  Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM , 2011, Comput. Methods Programs Biomed..

[49]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[50]  K. Cohen,et al.  Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients , 2008, European Journal of Clinical Pharmacology.

[51]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.